Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Respiratory & Allergy Oncology: Solid Tumors pelacarsen - ASO targeting Lp(a) Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04023552 Lp(a) HORIZON (CTQJ230A12301) Cardiovascular risk reduction Phase 3 7680 Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization) TQJ230 80 mg injected monthly subcutaneously or matched placebo Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) >= 70 mg/dL Target Patients Read-out Milestone(s) 2025 Publication TBD References Abbreviations Hematology Biosimilars Global Health 54 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation